Investigating how Cereblon affects Wnt signaling in colorectal cancer
Official title: A Cereblon signaling network in Wnt-driven cancers
Funded at Dartmouth College · NIH-11013408 · Data updated 2026-11-12
This study is looking at how a protein called Cereblon (CRBN) affects a signaling pathway important for colorectal cancer, with the hope of finding new ways to treat patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dartmouth College NIH-funded |
| Lab location | 1 site (Hanover, United States) |
| Project start | March 10, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $655,614 |
| NIH project number | 5R01CA281002-03 |
| Project ID | NIH-11013408 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Wnt-driven colorectal cancers.
✕Less likely to help
Patients with colorectal cancers not driven by the Wnt signaling pathway may not benefit from this research.
What this research studies
This research explores the role of Cereblon (CRBN) in regulating the Wnt signaling pathway, which is crucial for the development and progression of colorectal cancers (CRCs). By understanding how CRBN interacts with key proteins involved in this pathway, the research aims to identify new therapeutic targets for treating CRCs. The study utilizes various models, including human cells and animal models, to investigate the mechanisms by which CRBN influences Wnt signaling and cancer progression. If successful, this research could lead to the development of novel treatments for patients with Wnt-driven CRCs.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with colorectal cancer by targeting the Wnt signaling pathway.
How similar studies have gone: While the approach of targeting Wnt signaling is being explored, the specific role of Cereblon in this context is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Dartmouth College
Hanover, United States Active
Researchers
- Principal investigator: Ahmed, Yasmath — Dartmouth College
- Study coordinator: Ahmed, Yasmath
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.